<乌鸦传媒>ASCO's Quality Care Symposium: Chemotherapy Shortage Resulted in Higher Costs Other studies look at financial toxicity for teen/young adult cancer patients, nausea after chemo Sep 24, 2024
<乌鸦传媒>Immunotherapy May Not Benefit All Gastroesophageal Cancer Patients, FDA Staff Says Data since approvals suggest benefits limited to subgroups with PD-L1 expression of at least 1% Sep 24, 2024
<乌鸦传媒>EPA Scientists Say They Were Pressured to Downplay Health Harms From Chemicals And a watchdog found they were retaliated against Sep 22, 2024
<乌鸦传媒>High ADHD Medication Doses Tied to Psychosis; Rapid Tests for Malaria Also in TTHealthWatch: youth and opioids, and pembrolizumab for triple-negative breast cancer Sep 21, 2024 podcast
<乌鸦传媒>Earlier Info on Financial Stress; Obesity and Second Cancers; Carcinogenic Condoms? News, features, and commentary about cancer-related issues Sep 19, 2024
<乌鸦传媒>Rucaparib-Nivolumab Maintenance Not the Answer in Newly Diagnosed Ovarian Cancer Poorer survival outcomes plus more toxicity versus rucaparib alone Sep 18, 2024
<乌鸦传媒>Novel Agent Effective for Cancer Wasting Disorder Cancer patients with cachexia added needed pounds with GDF-15 antibody Sep 18, 2024
<乌鸦传媒>Lymphedema Risk No Higher With 3-Week RT Regimen in Early Breast Cancer "Nodal radiotherapy for breast cancer no longer needs 5 weeks," researcher says Sep 17, 2024
<乌鸦传媒>FDA Expands Approval of Ribociclib to Early Breast Cancer Broad indication doubles the number of patients eligible for adjuvant CDK4/6 inhibition Sep 17, 2024
<乌鸦传媒>Survival Win for Pembrolizumab in Early Triple-Negative Breast Cancer Absolute difference of 4.9% at 5 years, including a benefit for patients who did not achieve pCR Sep 17, 2024
<乌鸦传媒>Cabozantinib Improves PFS for Advanced Neuroendocrine Tumors Potential new option for patients with previously treated extrapancreatic or pancreatic NETs Sep 17, 2024
<乌鸦传媒>Digital Breast Tomosynthesis May Reduce Development of Advanced Cancers Retrospective study suggests benefits over digital mammography Sep 17, 2024
<乌鸦传媒>Win for Perioperative Durvalumab in Muscle-Invasive Bladder Cancer Results "practice-changing," says expert Sep 16, 2024
<乌鸦传媒>Medical Cannabinoids in Kids Linked to These Adverse Events Meta-analysis points to considerations for use and what to monitor Sep 16, 2024
<乌鸦传媒>Another Possible Treatment Option for Intermediate-Stage Liver Cancer Adding lenvatinib, pembrolizumab to TACE significantly improved PFS, numerically improved OS Sep 16, 2024
<乌鸦传媒>Chemo-Free Triplet Yields 68% Response Rate in Richter Transformation Regimen tops best historical response rate with chemoimmunotherapy in this setting Sep 16, 2024
<乌鸦传媒>Radionuclide-Containing Combo Slows Metastatic Prostate Cancer, Improves Survival Hazards for radiographic PFS, OS reduced by 31% with enzalutamide plus Ra-223 Sep 15, 2024
<乌鸦传媒>Retifanlimab-Chemo Combo Boosts PFS in Advanced Squamous Cell Anal Cancer POD1UM-303/InterAACT 2 data also trend in the direction of better overall survival Sep 15, 2024
<乌鸦传媒>No Survival Gain With Preoperative CRT Plus Perioperative Chemo for Gastric Cancer But combination may be appropriate for shrinking tumors before surgery Sep 14, 2024
<乌鸦传媒>Another Win for Antibody-Drug Conjugate in HER2+ Breast Cancer With Brain Mets Second-line T-DXd best option in patients with and without intracranial activity, experts says Sep 14, 2024
<乌鸦传媒>Screening After False Positive Mammograms; RSV Vaccination and Hospitalization Also in TTHealthWatch: time from approval to reimbursement for new drugs Sep 14, 2024 podcast
<乌鸦传媒>No PFS Benefit With Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma Data support that ICI rechallenge should be discouraged in patients with advanced RCC Sep 13, 2024
<乌鸦传媒>Cancer Diagnoses Still Lagging; Cancer and Family Health; New Type of Lung Cancer News, features, and commentary about cancer-related issues Sep 12, 2024
<乌鸦传媒>How a California Oncologist Making $850k Spends Money See the breakdown of this physician's weekly budget, from eating out to sailing lessons Sep 12, 2024
<乌鸦传媒>Second Malignancy Risk With CAR T-Cell Therapy on Par With Other Treatments Incidence almost identical to that with standard cancer treatment in randomized trials Sep 11, 2024
<乌鸦传媒>Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC Objective response rate was 55% with 12-mg/kg ifinatamab deruxtecan Sep 11, 2024
<乌鸦传媒>Limits to Anti-Nausea Pill Coverage Wear on Cancer Patients and Doctors "This is sort of the dirty underbelly of the current healthcare environment," an oncologist said Sep 11, 2024
<乌鸦传媒>Added Plinabulin Boosts OS as Later-Line Treatment for EGFR Wild-Type NSCLC However, plinabulin plus docetaxel still "not ready for prime time," expert says Sep 10, 2024
<乌鸦传媒>MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC Absolute improvement of almost 30%, doubling of duration of response with savolitinib Sep 10, 2024
<乌鸦传媒>Did U.S. Government Play a Role in Remote Tribe's Widespread Illness and Cancer? Toxins are embedded in the soil, but no one can say what has caused such widespread illness Sep 10, 2024
<乌鸦传媒>Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC Two-trial analysis shows about a 40% decreased risk of disease recurrence or death Sep 09, 2024
<乌鸦传媒>Study Supports Lactated Ringer Solution for Fluid Resuscitation in SCD For patients with vaso-occlusive episodes, lactated Ringer was better than normal saline Sep 09, 2024
<乌鸦传媒>Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC Novel agent nearly halved risk of progression as first-line therapy in phase III trial Sep 09, 2024
<乌鸦传媒>Kate Middleton Reaches Cancer Treatment Milestone Princess of Wales says she will return to some public duties Sep 09, 2024
<乌鸦传媒>Novel Drugs Boost Immunotherapy Activity in Resectable Lung Cancer Add-on ADC, monoclonal antibody consistently increase pCR versus PD-1 inhibitor plus chemotherapy Sep 09, 2024
<乌鸦传媒>Comparing Fecal Immunochemical Tests; CVD Blood Test for Women Also in TTHealthWatch: beta-blockers after MI Sep 07, 2024 podcast
<乌鸦传媒>Study Backs Skipping 5-FU Bolus in Chemo Regimens for Gastrointestinal Cancers No difference in overall survival with versus without bolus, less toxicity without Sep 05, 2024
<乌鸦传媒>Women With HCC Less Likely to Receive Liver Transplant, More Likely to Die Than Men This difference is mostly explained by their smaller stature, researchers say Sep 05, 2024
<乌鸦传媒>No Cellphone, Brain Cancer Link; Testosterone Paradox; Breast Density and Cancer News, features, and commentary about cancer-related issues Sep 05, 2024
<乌鸦传媒>The Truth About Apple AirPods Dr. Mike looks at the research on electromagnetic fields Sep 05, 2024
